Enlarge / Packing containers of Johnson & Johnson’s Janssen COVID-19 vaccine at a vaccination website in Florida. (credit score: Getty | Paul Hennessy)

A committee of impartial advisors for the Meals and Drug Administration on Friday voted unanimously in favor of authorizing a second dose of the Johnson & Johnson COVID-19 vaccine to everybody 18 years of age and older, two or extra months after an individual has acquired the primary dose.

It’s the third time the FDA’s advisory committee has beneficial extra COVID-19 doses in latest weeks to bolster safety. However the reviewed information, dialogue, and vote at this time had been considerably totally different from the booster-authorization conferences for Pfizer/BioNTech and Moderna COVID-19 vaccines.

Dose two

The J&J vaccine has persistently lagged behind the 2 mRNA vaccines in efficacy in opposition to COVID-19. Some estimates have put the J&J vaccine’s effectiveness in opposition to COVID-19 hospitalization as little as 68 p.c, whereas the 2 mRNA vaccines have seen estimates of effectiveness in opposition to hospitalization within the excessive 80s to low 90s. Current information means that the mRNA vaccines’ safety in opposition to an infection might begin waning six or extra months after major doses—significantly in older and extra weak individuals. This information prompted the push for boosters. However such waning doesn’t seem like occurring with the J&J vaccine.